Paige Review
VisitAI-powered pathology intelligence for cancer diagnostics
Paige is an AI platform that assists pathologists in detecting and analyzing cancer in digital pathology slides.
AI Panel Score
7.9/10
6 AI reviews
Reviewed
AI-powered pathology intelligence for cancer diagnostics
Paige is an AI platform that assists pathologists in detecting and analyzing cancer in digital pathology slides.
AI Panel Score
6 AI reviews
Reviewed
Paige is an AI-driven digital pathology company that develops software tools to assist pathologists in analyzing whole slide images (WSIs) for cancer detection and diagnosis. The platform applies deep learning algorithms trained on extensive repositories of annotated pathology data to help identify areas of concern in tissue samples, with a focus on improving diagnostic accuracy and workflow efficiency in clinical environments.
The company's flagship product, Paige Prostate, was the first FDA-authorized AI product for use in surgical pathology, designed to help pathologists detect prostate cancer in biopsy slides. Paige has since expanded its portfolio to include tools targeting other cancer types and diagnostic workflows, positioning itself as a comprehensive AI solution for anatomic pathology labs.
Paige is primarily aimed at pathologists, health systems, academic medical centers, and reference laboratories seeking to integrate AI assistance into their diagnostic workflows. The software works alongside existing digital pathology infrastructure, including whole slide image scanners and laboratory information systems, rather than replacing existing processes.
In the broader digital pathology market, Paige competes with other AI-assisted pathology platforms and traditional image analysis tools. Its FDA authorization distinguishes it from many research-only tools, as it is cleared for use in clinical decision support. The company has partnerships with major healthcare institutions and pathology equipment manufacturers to expand adoption.
Pricing and deployment terms for Paige are typically negotiated directly with healthcare institutions and are not publicly listed, reflecting the enterprise and clinical nature of the product. Organizations interested in the platform would engage with Paige's sales team for evaluation and implementation details.
A multi-modal co-pilot that integrates AI with voice and text commands to streamline pathologists' cancer detection and diagnosis workflows and provide real-time insights.
A set of AI applications designed to support pathologists in the identification and classification of breast cancer on H&E-stained whole-slide images from breast biopsy and excision specimens.
A portfolio of AI-powered applications designed to support pathologists in the detection and classification of benign and malignant conditions across the entire gastrointestinal tract.
An AI suite trained on over 1.5 million slides that helps pathologists identify subtle complexities of cancer in multiple tissue types, including rare cancers.
A group of comprehensive AI applications that aid in the detection and diagnosis of prostate cancer on H&E-stained whole-slide images of prostate needle biopsies.
Pre-built pan-cancer modules that enable precise therapeutic targeting, novel biomarker identification, and optimized clinical trial design.
AI technology that reveals multiple molecular biomarkers directly from tissue samples without requiring separate molecular testing.
Proprietary foundation models including Virchow, Virchow2, Virchow2G, and Virchow2G-Mini that eliminate the need for task-specific training to accelerate computational pathology AI development.
A foundation model technology developed by Paige as part of its suite of computational pathology AI models for cancer research and diagnostics.
Services for developing customized prognostic or predictive AI models leveraging Paige's foundation model technology while adhering to privacy, security, and clinical standards.
Comprehensive services that help partners navigate regulatory hurdles and develop a strategy for bringing computational pathology AI applications to market.
Paige licenses its AI pathology suite (FullFocus, Prostate Suite, Breast Suite, etc.) to hospitals, labs, and biopharma. Pricing is per-site or per-pipeline and scoped to the deployment. Contact sales.
First FDA-authorized surgical pathology AI, built on 1.5 million slides.
“Paige owns a defensible regulatory moat in a market where most competitors are still research-only. The tradeoff is a slow, negotiated enterprise sales process with zero pricing transparency.”
Paige Prostate was the first FDA-authorized AI in surgical pathology. That's not marketing — that's a regulatory wall competitors like Philips IntelliSite or Aiforia haven't fully crossed yet. The Virchow foundation models and PanCancer Suite trained on 1.5 million slides suggest serious infrastructure investment, not a feature sprint.
The pitch isn't cost savings. It's diagnostic accuracy and rare cancer catch rates. That's a strategic advance, not an efficiency play — and it's a defensible answer when the board asks why you spent the budget. Paige Alba adding voice and text co-pilot workflows inside the diagnostic loop is a meaningful differentiator, not a demo feature.
Two real concerns. One: no public pricing, no changelog, no API docs visible — enterprise deals move slowly and you won't know the renewal math until year two. Two: the clinical validation claims need your own legal and compliance review before any board conversation.
FDA clearance and 1.5 million training slides create a moat most research-only competitors — including Aiforia — haven't matched.
First FDA-authorized surgical pathology AI is a credible board answer; adopting it reads as leadership, not experimentation.
Contact-only pricing and enterprise deployment cycles mean months before the first slide runs through a live workflow.
PanCancer Suite and Molecular Biomarker Discovery move labs toward precision oncology, not just workflow automation.
FDA authorization, major health system partnerships, and a proprietary foundation model stack suggest durable investment — no public funding data, but category gravity keeps them relevant.
Academic medical centers and reference labs ready to lead on AI-assisted oncology diagnostics.
Your organization isn't ready for a negotiated enterprise contract with no self-serve evaluation path.
First FDA-authorized surgical pathology AI with foundation model depth that justifies serious clinical evaluation.
“Paige holds a rare regulatory position — FDA authorization for clinical decision support distinguishes it from every research-only competitor in the space. The Virchow foundation model family and 1.5M-slide training corpus signal genuine platform ambition, not a point solution.”
Paige Prostate was the first FDA-authorized AI in surgical pathology — that's not a marketing claim, it's a regulatory milestone that changes procurement conversations entirely. For any health system's CMO, the difference between FDA-authorized clinical decision support and a research-grade tool is the difference between deployment and a pilot that never ends. Competitors like PathAI and Proscia haven't cleared that bar uniformly across cancer types.
The portfolio breadth is real: Prostate Suite, Breast Suite, GI Suite, PanCancer Suite trained on 1.5 million slides, plus Paige Alba as a multimodal co-pilot. That's a pathology lab architecture, not a feature list. If we adopt this, in three years we have a single AI layer spanning most anatomic pathology workflows rather than managing four point-solution vendors.
The tradeoff is pricing opacity — enterprise-only, contact sales, no public tier structure. For a health system CFO alignment conversation, that's friction. Integration evidence is also thin: the docs and API indicators show N, which raises real questions about LIS connectivity depth before any contract is signed.
First-mover FDA authorization plus a 1.5M-slide training corpus positions Paige ahead of PathAI and Proscia in clinical-grade credibility for health system procurement.
Whole-slide image workflow integration, H&E-stained slide support, and pathologist-facing co-pilot (Paige Alba) reflect deep understanding of anatomic pathology lab operations.
No public API documentation and no changelog visibility make it difficult to assess LIS and scanner interoperability depth prior to a formal evaluation engagement.
FDA authorization creates a defensible deployment path, but custom AI development services and regulatory strategy offerings create meaningful lock-in on the foundation model layer over a 3-year horizon.
Virchow foundation model family plus regulatory strategy services signal a platform built for durable clinical and biopharma utility, not a demo-grade detector.
Academic medical centers and reference labs seeking FDA-authorized AI across multiple cancer types in a single platform.
Your pathology lab lacks a digital scanning infrastructure, since Paige requires existing whole-slide image pipeline investment to deploy.
1.5M training slides, zero public pricing — pure enterprise negotiation territory
“Paige is FDA-authorized clinical AI for pathology, first cleared for surgical pathology in its category. Zero pricing transparency; every number lives behind a sales call.”
No pricing page. No tiers. No per-slide, per-site, or per-seat anchors published anywhere. The only public number: PanCancer Suite trained on 1.5 million slides. Everything else — deployment cost, integration fees, annual contract value — is scoped deal by deal. That's standard for clinical enterprise software, but it makes TCO modeling nearly impossible pre-contract.
Year 1 cost is unknown. Year 3 is unknowable without a signed agreement. Integration with existing whole-slide image scanners and LIS systems adds implementation cost category norms peg at 20-40% of license value. No public overage rates, no published auto-renewal windows. Competitors like PathAI operate the same playbook — opaque pricing, negotiated terms — so Paige isn't unusual, just expensive to evaluate.
Tradeoff is real: FDA authorization justifies procurement friction for clinical buyers. Research-only labs get less value. ROI story depends entirely on volume — high-throughput reference labs can model cost-per-slide savings; low-volume academic centers can't.
Contact-only model with no invoicing structure disclosed; procurement cycle will be lengthy and legally intensive.
No public auto-renewal terms, cancellation clauses, or term lengths; standard enterprise opaqueness.
No published pricing page; all terms require direct sales engagement per the evidence.
FDA authorization and 1.5M-slide training data support a defensible clinical ROI narrative, but dollar-per-slide savings aren't published.
Per-site or per-pipeline model noted, but no rate cards — integration and training costs are unquantifiable pre-contract.
High-volume reference labs or health systems with dedicated procurement resources and existing digital pathology infrastructure.
Budget-constrained academic centers or any buyer who needs predictable, published pricing before initiating procurement.
First FDA-authorized AI in surgical pathology, and it shows in the clinical depth
“Paige Prostate was the first FDA-authorized AI product in surgical pathology — that regulatory moat is real and rare. The suite has grown substantially, but daily workflow fit depends heavily on how well your lab's scanner infrastructure and LIS play along.”
Paige Prostate's FDA clearance isn't a marketing badge — it's what separates this from the dozens of research-only tools competing for pathology lab attention. The PanCancer Suite trained on 1.5 million slides, and the Virchow foundation model enabling custom AI development is genuinely differentiated architecture. Competitors like Proscia and PathAI don't have that regulatory track record baked in.
The Alba co-pilot with voice and text commands is the feature I'd be watching on day three. Real-time voice interaction during slide review sounds compelling in a demo; whether it survives the actual noise and pace of a busy surgical pathology grossing room is the unresolved question. No changelog is public, so tracking model updates or drift over time requires a direct relationship with their team.
No public pricing, no free trial, no API docs visible. For a solo or community hospital pathologist, the enterprise-only sales motion creates real friction before you've seen a single slide. Academic centers with digital pathology infrastructure already in place will integrate far more smoothly than labs still on glass.
FDA clearance and multi-cancer suite breadth hold up past the demo, but no changelog or public model versioning means post-deployment visibility depends on your sales rep.
No changelog, no visible API documentation, and buyer questions about privacy frameworks get vague answers — docs appear written for procurement conversations, not pathologists.
No public API docs and no self-serve trial means every integration question goes through enterprise sales, which adds latency for labs trying to evaluate fit.
Virchow foundation models plus Custom AI Development Services and Regulatory Strategy Services give computational pathology teams genuine depth well beyond detection overlays.
Designed to layer onto existing WSI scanners and LIS rather than replace them — that's the right architecture for pathology labs, and the FullFocus viewer is included in the enterprise tier.
Academic medical centers and reference labs with digital pathology infrastructure already in place seeking FDA-cleared AI support across prostate, breast, and GI cancer workflows.
Your lab hasn't yet digitized slides or you need a self-serve evaluation path before committing to an enterprise contract.
First FDA-authorized AI in surgical pathology, and it shows
“Paige Prostate was the first FDA-authorized AI for surgical pathology, and the portfolio has grown into something serious. This is enterprise clinical infrastructure, not a SaaS trial signup.”
Paige isn't a tool you evaluate on a free tier. It's clinical infrastructure, priced per-site by a sales team, deployed into hospital labs running whole-slide image scanners. The PanCancer Suite trained on over 1.5 million slides is a real number with real weight behind it. Foundation models like Virchow and PRISM mean the underlying tech isn't borrowed — Paige built the stack.
The portfolio breadth is genuinely impressive: Prostate Suite, Breast Suite, GI Suite, PanCancer, plus Paige Alba as a voice-and-text co-pilot for live workflows. That's not feature padding. That's coverage across real diagnostic workloads. Competitors like Proscia and PathAI are building similar territory, but FDA clearance is still Paige's sharpest edge.
The tradeoff is total opacity on everything a new buyer actually needs. No pricing page, no changelog, no docs. Web-only, no mobile parity to speak of — which is fine for a pathology workstation product but worth naming. Day three, you're deep in a procurement conversation, not a product evaluation. That's just how this category works.
Paige Alba's voice-and-text co-pilot suggests real workflow thinking, but no changelog or public UI details make this hard to fully assess.
The modular suite structure across Prostate, Breast, GI, and PanCancer suggests progressive adoption is possible, but there's no public documentation to verify discoverability.
Web-only platform built for pathology workstations — mobile isn't the point, but it's also not a product.
No free trial, no free plan, no docs — onboarding is a sales engagement, not a product experience, which is category-standard but still friction.
FDA authorization for clinical use implies a reliability bar that most software never has to clear; that's a meaningful signal.
Hospital pathology labs, academic medical centers, and reference labs that need FDA-cleared AI across multiple cancer types and have procurement infrastructure to match.
You need a self-service evaluation path, transparent pricing, or anything beyond a desktop workstation workflow.
First FDA-cleared surgical pathology AI — that's a real moat, not a marketing line
“Paige Prostate was genuinely the first FDA-authorized AI for surgical pathology. That's not a footnote — it's a meaningful regulatory barrier most competitors haven't cleared. The portfolio breadth (Breast, GI, PanCancer, 1.5M-slide Virchow foundation models) suggests serious infrastructure, not a one-trick vendor.”
Three tells. One: no pricing page, no changelog, no API docs visible. Enterprise-only contact sales is fine for this category — Proscia and PathAI operate similarly — but the opacity compounds quickly if you're evaluating seriously. Two: 'solve cancer's most critical issues' is the kind of H1 that ages poorly. Big claim, no grounding on the landing page. Three: the Virchow foundation model family (Virchow, Virchow2, Virchow2G) suggests genuine R&D depth — that's not typical feature-list padding.
Two flags. Exit portability is rough. No API visible, no data export docs, and the whole-slide image infrastructure locks into their FullFocus viewer and lab workflow integrations. If they pivot or get acquired — and pathology AI M&A has been active — you're renegotiating from a weak position. Also, PanCancer covers rare cancers but won't enumerate tissue types publicly. That vagueness matters in clinical procurement.
Fair verdict: FDA clearance plus 1.5 million training slides plus named pharma R&D partnerships puts Paige ahead of most research-only tools. Not ahead of everything — PathAI has comparable clinical reach. But the regulatory moat is real, and this doesn't look like a two-year shutdown candidate.
FDA clearance for Paige Prostate and the 1.5M-slide PanCancer training set differentiate meaningfully from research-only tools; PathAI is the closest credible rival with similar clinical positioning.
No public API, no data portability docs, and deep integration with proprietary FullFocus viewer makes clean migration unlikely without a costly renegotiation.
No changelog or public funding data visible, but pharma R&D partnerships and a named foundation model family (Virchow2G-Mini through full Virchow2G) suggest active, funded development — not a stalled product.
'Solve cancer's most critical issues' is unsupported superlative; the FDA-clearance claim is verifiable and grounded, which saves it from a lower score.
First FDA-authorized AI for surgical pathology is a documented first-mover fact; Virchow foundation model publications suggest real research output, not vaporware.
Hospital pathology labs and academic medical centers that need FDA-cleared AI and can absorb enterprise procurement cycles.
You need transparent pricing, API access, or a clean exit path before committing to infrastructure integration.
Common questions answered by our AI research team
The Paige PanCancer Suite is trained on over 1.5 million slides (using the Virchow foundation model) and helps pathologists identify cancer across multiple tissue types. It explicitly supports rare cancer detection, described as able to "identify the most subtle complexities of cancer in multiple tissue types including rare cancers." Specific tissue types covered are not enumerated in the content.
The content states that licensing Paige's foundation models enables custom AI model development that adheres to "the highest standards of privacy, security, and clinical excellence," but no specific privacy frameworks, certifications, or security standards are detailed.
Paige is a New York-based healthcare AI company that builds diagnostic tools for cancer pathology.
